Compare DraftKings Inc (DKNG) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs McKesson Corporation — how do they compare? DraftKings Inc trades at $19.9 (market cap $9.51B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 11.2× DraftKings Inc's market cap, and McKesson Corporation pays a 0.41% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and McKesson Corporation for 74 Days on average.
| DKNG | MCK | |
|---|---|---|
Market Cap | $9.51B | $106.14B |
Volume | 11,829,779 | 794,405 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $995.69 |
52-Week Low | $18.59 | $725.17 |
Typical Hold Time | 55 Days | 74 Days |
Enterprise Value | $10.44B | $112.67B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.15, down 3.04% on the day and near its 52-week low of $18.95, reflecting bearish technical momentum. Fundamentally, revenue grew to $6.05 billion in 2025 with a slight net profit of $3.71 million, but recent quarterly EPS misses and a negative net income margin of -2.68% for 2026 highlight profitability challenges. The stock's high P/E of 246.33 signals premium valuation despite operational improvements, including positive operating cash flow of $662.86 million in 2025.
The outlook is mixed: strong analyst consensus (75% buy ratings) and a $33.13 price target suggest upside potential from sportsbook growth and prediction market expansion, but risks include competitive pressures, regulatory uncertainty from Brazil's betting ban, and volatility from high valuation multiples. Investors face a trade-off between long-term growth prospects and near-term earnings instability.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
